Innoviva Pre-Tax Profit Margin 2010-2024 | INVA
Innoviva pre-tax profit margin from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Innoviva Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$0.35B |
$0.07B |
20.96% |
| 2024-06-30 |
$0.33B |
$0.15B |
46.36% |
| 2024-03-31 |
$0.31B |
$0.20B |
63.67% |
| 2023-12-31 |
$0.31B |
$0.19B |
62.58% |
| 2023-09-30 |
$0.29B |
$0.07B |
23.45% |
| 2023-06-30 |
$0.29B |
$0.27B |
92.41% |
| 2023-03-31 |
$0.32B |
$0.28B |
88.96% |
| 2022-12-31 |
$0.33B |
$0.29B |
86.40% |
| 2022-09-30 |
$0.37B |
$0.41B |
109.12% |
| 2022-06-30 |
$0.40B |
$0.24B |
60.40% |
| 2022-03-31 |
$0.40B |
$0.36B |
90.68% |
| 2021-12-31 |
$0.39B |
$0.44B |
112.98% |
| 2021-09-30 |
$0.38B |
$0.48B |
127.73% |
| 2021-06-30 |
$0.37B |
$0.41B |
110.93% |
| 2021-03-31 |
$0.34B |
$0.39B |
112.79% |
| 2020-12-31 |
$0.34B |
$0.35B |
105.04% |
| 2020-09-30 |
$0.32B |
$0.33B |
103.10% |
| 2020-06-30 |
$0.30B |
$0.34B |
113.67% |
| 2020-03-31 |
$0.29B |
$0.28B |
97.89% |
| 2019-12-31 |
$0.26B |
$0.23B |
89.27% |
| 2019-09-30 |
$0.27B |
$0.24B |
89.06% |
| 2019-06-30 |
$0.26B |
$0.23B |
87.36% |
| 2019-03-31 |
$0.26B |
$0.23B |
86.74% |
| 2018-12-31 |
$0.26B |
$0.21B |
80.46% |
| 2018-09-30 |
$0.25B |
$0.20B |
78.09% |
| 2018-06-30 |
$0.24B |
$0.17B |
71.43% |
| 2018-03-31 |
$0.23B |
$0.15B |
64.35% |
| 2017-12-31 |
$0.22B |
$0.14B |
61.93% |
| 2017-09-30 |
$0.19B |
$0.10B |
53.13% |
| 2017-06-30 |
$0.18B |
$0.09B |
52.84% |
| 2017-03-31 |
$0.15B |
$0.07B |
48.99% |
| 2016-12-31 |
$0.13B |
$0.06B |
45.11% |
| 2016-09-30 |
$0.11B |
$0.04B |
33.93% |
| 2016-06-30 |
$0.09B |
$0.02B |
19.35% |
| 2016-03-31 |
$0.07B |
$-0.01B |
-6.94% |
| 2015-12-31 |
$0.06B |
$-0.02B |
-36.36% |
| 2015-09-30 |
$0.04B |
$-0.04B |
-102.56% |
| 2015-06-30 |
$0.03B |
$-0.06B |
-219.23% |
| 2015-03-31 |
$0.02B |
$-0.07B |
-431.25% |
| 2014-12-31 |
$0.01B |
$-0.07B |
-925.00% |
| 2014-09-30 |
$0.00B |
$-0.04B |
-2000.00% |
| 2014-06-30 |
$0.00B |
$-0.03B |
-2700.00% |
| 2014-03-31 |
$0.00B |
$-0.01B |
-900.00% |
| 2013-12-31 |
$0.00B |
$-0.03B |
-1000.00% |
| 2013-09-30 |
$0.01B |
$-0.08B |
-987.50% |
| 2013-06-30 |
$0.01B |
$-0.11B |
-1166.67% |
| 2013-03-31 |
$0.01B |
$-0.14B |
-1555.56% |
| 2012-12-31 |
$0.14B |
$-0.02B |
-13.33% |
| 2012-09-30 |
$0.13B |
$-0.02B |
-17.91% |
| 2012-06-30 |
$0.14B |
$-0.02B |
-14.39% |
| 2012-03-31 |
$0.14B |
$-0.01B |
-5.56% |
| 2011-12-31 |
$0.02B |
$-0.12B |
-504.35% |
| 2011-09-30 |
$0.03B |
$-0.10B |
-392.00% |
| 2011-06-30 |
$0.02B |
$-0.09B |
-366.67% |
| 2011-03-31 |
$0.02B |
$-0.08B |
-350.00% |
| 2010-12-31 |
$0.02B |
$-0.08B |
-350.00% |
| 2010-09-30 |
$0.02B |
$-0.09B |
-414.29% |
| 2010-06-30 |
$0.02B |
$-0.09B |
-400.00% |
| 2010-03-31 |
$0.02B |
$-0.09B |
-423.81% |
| 2009-12-31 |
$0.03B |
$-0.09B |
-340.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.195B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
